Arizona Health Sciences Center, Assistant Professor of Medicine, Director of IBD Program
A: Thanks for your question. Generally, the chances of your disease worsening are based on the severity of your disease at diagnosis. The severity of your disease is based on your clinical symptoms, labs, imaging, and the endoscopic evaluation. For instance, if you had mild Crohn’s disease at diagnosis, the risk of the disease progressing is lower than if you had moderate or severe Crohn’s disease at diagnosis. Your GI can help determine where you fall in the mild, moderate, and severe range. It is very reasonable to reevaluate your disease as your new GI has suggested prior to starting medications like infliximab/adalimumab (aka Remicade/Humira). hide answer
A: That’s an interesting question. With infliximab (Remicade), some providers use steroids (like prednisone) before the infusion with the thought that it prevents infusion reactions. For adalimumab (Humira), I have found that using allergy drugs like diphenhydramine (Benadryl) can be effective in preventing injection site reactions. I have not use steroids with adalimumab in the past to prevent injection site reactions. hide answer
A: I would need more information on this situation to be able to answer this question adequately. hide answer
A: This is a common scenario and I am glad that you brought it up. We know that there is a group of patients with Crohn’s or ulcerative colitis who have ongoing pain without evidence of active intestinal inflammation. The pain can be due to multiple causes including small bowel bacterial overgrowth, musculoskeletal pain, irritable bowel syndrome, etc. It’s important to work with your gastroenterologist to determine the cause of the pain so it can be adequately managed. hide answer
A: This mutation may have some relation to the development of IBD. It may place a patient at higher risk for clotting and it is associated with other disease processes so it is not specific for IBD. There have been over 200 different gene mutations found that are associated with IBD. The reality is that most patients do not have any of these mutations because IBD involves a complex interplay between organisms in the gut, environment factors like smoking, and an overactive immune system. hide answer